Tudor Investment Corp ET AL increased its position in Lannett Co Inc (NYSE:LCI) by 49.5% during the first quarter, according to its most recent 13F filing with the SEC. The firm owned 14,800 shares of the company’s stock after buying an additional 4,900 shares during the period. Tudor Investment Corp ET AL’s holdings in Lannett Co were worth $331,000 at the end of the most recent quarter.
A number of other hedge funds also recently modified their holdings of LCI. Westwood Holdings Group Inc. boosted its stake in shares of Lannett Co by 22.5% in the first quarter. Westwood Holdings Group Inc. now owns 181,832 shares of the company’s stock worth $4,064,000 after buying an additional 33,340 shares during the period. Gotham Asset Management LLC boosted its stake in shares of Lannett Co by 12.4% in the first quarter. Gotham Asset Management LLC now owns 695,498 shares of the company’s stock worth $15,544,000 after buying an additional 76,892 shares during the period. Highbridge Capital Management LLC bought a new stake in shares of Lannett Co during the first quarter worth about $287,000. State Street Corp boosted its stake in shares of Lannett Co by 7.9% in the first quarter. State Street Corp now owns 1,279,860 shares of the company’s stock worth $28,606,000 after buying an additional 93,186 shares during the period. Finally, Schwab Charles Investment Management Inc. boosted its stake in shares of Lannett Co by 26.9% in the first quarter. Schwab Charles Investment Management Inc. now owns 144,627 shares of the company’s stock worth $3,233,000 after buying an additional 30,626 shares during the period. 95.20% of the stock is currently owned by institutional investors and hedge funds.
Lannett Co Inc (LCI) opened at 21.75 on Friday. The company’s market capitalization is $809.75 million. The firm has a 50-day moving average price of $20.26 and a 200-day moving average price of $21.54. Lannett Co Inc has a 52 week low of $16.75 and a 52 week high of $39.99.
Lannett Co (NYSE:LCI) last announced its quarterly earnings data on Tuesday, May 2nd. The company reported $0.77 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.87 by $0.10. Lannett Co had a negative net margin of 0.41% and a positive return on equity of 22.13%. The business had revenue of $165.72 million during the quarter, compared to analysts’ expectations of $170.28 million. Analysts anticipate that Lannett Co Inc will post $3.21 EPS for the current fiscal year.
A number of brokerages recently issued reports on LCI. Zacks Investment Research upgraded Lannett Co from a “hold” rating to a “buy” rating and set a $25.00 target price on the stock in a research note on Tuesday. Deutsche Bank AG restated a “hold” rating and issued a $23.00 target price (up from $22.00) on shares of Lannett Co in a research note on Monday. Oppenheimer Holdings, Inc. restated a “hold” rating on shares of Lannett Co in a research note on Thursday, June 8th. ValuEngine lowered Lannett Co from a “buy” rating to a “hold” rating in a research note on Friday, June 2nd. Finally, Roth Capital set a $27.00 target price on Lannett Co and gave the stock a “buy” rating in a research note on Tuesday, May 2nd. Five analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Lannett Co has a consensus rating of “Hold” and an average price target of $27.50.
Lannett Co Company Profile
Lannett Company, Inc develops, manufactures, markets and distributes generic versions of brand pharmaceutical products. The Company manufactures and/or distributes prescription products with the exception of a small portfolio of over-the-counter products manufactured by its subsidiary, Silarx Pharmaceuticals, Inc As of June 30, 2016, the Company’s products included Acetazolamide Tablets; Butalbital, Acetaminophen and Caffeine Tablets; Butalbital, Aspirin and Caffeine Capsules; C-Topical Solution; Digoxin Tablets; Glycolax Rx; Isosorbide Mononitrate CR; Levothyroxine Sodium Tablets; Methylphenidate HCL CD; Methylphenidate ER; Nifedipine CR; Omeprazole DR; Oxbutynin ER; Pantoprazole DR; Pilocarpine HCl Tablets; Triamterene w/Hydrochlorothiazide Capsules, and Ursodiol Capsules.
Want to see what other hedge funds are holding LCI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Lannett Co Inc (NYSE:LCI).
Receive News & Ratings for Lannett Co Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lannett Co Inc and related companies with MarketBeat.com's FREE daily email newsletter.
